ArticleBMC pregnancy and childbirth2025
ORAI1, FGF23, PP13, palladin, and supervillin as potential biomarkers in late-onset pre-eclampsia: a comparative study in maternal and cord blood.
Article in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular Insights into Human Placentation: From Villous Morphogenesis to Pathological Pathways and Translational Biomarkers.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPre-eclampsia continues to be a significant global health burden with complex pathophysiology, necessitating investigation of novel biomarkers to improve understanding, diagnosis and management of this pregnancy-specific disorder.To investigate the differential expression of Calcium Release-Activated Calcium Channel Protein 1 (ORAI1), Fibroblast Growth Factor 23 (FGF23), Placental Protein 13 (PP13), Palladin, and Supervillin in both maternal and umbilical cord blood as potential biomarkers for late-onset pre-eclampsia.
methodsThis cross-sectional, case-control study included 61 women with late-onset pre-eclampsia and 61 normotensive pregnant women undergoing cesarean delivery. Maternal blood samples were collected immediately prior to cesarean delivery, and umbilical cord blood was obtained immediately after delivery of the placenta. Protein concentrations in both circulatory compartments were measured using enzyme-linked immunosorbent assay. The unique study design with paired maternal-cord blood sampling provided insights into maternal-fetal protein transfer dynamics in pre-eclamptic conditions.
resultsMaternal and cord blood ORAI1 concentrations were significantly elevated in pre-eclampsia (p = 0.001 and p = 0.035, respectively), while FGF23 and PP13 were significantly decreased in maternal blood (p = 0.022 and p = 0.018, respectively). Maternal-to-cord blood concentration ratios for ORAI1 and FGF23 were significantly altered in pre-eclampsia (p = 0.038 and p = 0.021, respectively). ORAI1 showed the highest diagnostic accuracy (AUC = 0.733) and correlated positively with disease severity and negatively with birth weight. Combined ORAI1 and FGF23 assessment significantly enhanced diagnostic performance (AUC = 0.782).
conclusionThe altered expression of ORAI1, FGF23, and PP13 in late-onset pre-eclampsia suggests disruptions in calcium signaling, phosphate metabolism, and placental function. The parallel measurement of these proteins in both maternal and cord blood provided unique insights into maternal-fetal interface dysfunction in pre-eclampsia. The superior performance of combined ORAI1 and FGF23 measurement underscores the value of a multi-marker approach in capturing pre-eclampsia's complex pathophysiology, potentially contributing to improved diagnostic strategies and therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.